Despite a GAAP net loss, Ligand Pharmaceuticals Inc (LGND) showcases robust financial health and promising new ventures in ...

In a report released today, Trevor Allred from Oppenheimer reiterated a Buy rating on Ligand Pharma (LGND – Research Report), with a price ...

Ligand Pharmaceuticals Inc (NASDAQ:LGND) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for ...

Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) is expected to announce its earnings results before the market opens ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ligand Pharma (LGND – Research Report), GoodRx Holdings ...

Good morning everyone and welcome to Ligand’s Fourth Quarter and Full Year 2024 Earnings Call. During the call today, we will review the financial results we released earlier today and provide ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

New York State Common Retirement Fund lifted its holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Free Report) ...

Ligand Pharmaceuticals Inc. (LGND) ...